Esketamine: A Fast-Acting Treatment for Depression, Explained (Hough, FDA, 2019)
Introduction: In 2019, the FDA approved esketamine, a nasal spray developed for people with treatment-resistant depression (TRD). This report by […]
Introduction: In 2019, the FDA approved esketamine, a nasal spray developed for people with treatment-resistant depression (TRD). This report by […]
Introduction: In 2019, the FDA’s Psychopharmacologic Drugs Advisory Committee (PDAC) and Drug Safety and Risk Management Advisory Committee (DSaRM) evaluated
Introduction: The FDA reviewed a new treatment called esketamine, a nasal spray developed for people with treatment-resistant depression (TRD). TRD
Introduction: Ketamine and esketamine are increasingly investigated for their potential in managing TRD. This systematic review examines clinical trials registered
Introduction: Ketamine and esketamine have been explored in medical research for treating treatment-resistant depression (TRD), a severe form of depression
Introduction: The FDA’s drug approval process ensures that new therapies meet high standards of safety and efficacy before they are
Introduction: The U.S. Food and Drug Administration (FDA) plays a crucial role in ensuring the safety and effectiveness of medications.
Introduction The study by Vekhova et al. (Oct 2024) presents a comprehensive review of ketamine and esketamine’s evolving role in
Introduction A recent study by Vekhova, Namiot, Jonsson, and Schiöth (Oct 2024) explores the growing use of ketamine and esketamine